Document:

EX-10.35

 Exhibit 10.35 

CHAIRMAN AGREEMENT 
 This
CHAIRMAN AGREEMENT (the “Agreement”) is entered into effective as of October 23, 2013 (the “Effective Date”), by and between PURE
BIOSCIENCE, INC., a Delaware corporation (the “Company”), and DAVE PFANZELTER (the “Chairman”). The Company and the
Chairman are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”. 

RECITALS 

A. The Company desires assurance of the continued association and services of the Chairman in order to retain his experience, skills,
abilities, background and knowledge, and is willing to appoint the Chairman to the Company’s Board of Directors (the “Board”) on the terms and conditions set forth in this Agreement. 

B. The Chairman desires to serve on the Board as Chairman of the Board, and is willing to accept such continued service on the terms
and conditions set forth in this Agreement. 
 C. The Company and the Chairman desire to, among other things, provide for benefits
payable to the Chairman upon certain events and reflect the application of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) to the benefits that may be provided to the Chairman. 

AGREEMENT 

In consideration of the foregoing recitals and the mutual promises and covenants herein contained, and for other good and valuable
consideration, the Parties, intending to be legally bound, agree as follows: 
 1. APPOINTMENT AS CHAIRMAN. 

1.1 Appointment. The Board shall appoint Chairman as Chairman of the Board. 

1.2 Term. The Board hereby appoints the Chairman, and the Chairman hereby accepts such appointment by the Board, as Chairman of the
Board upon the terms and conditions set forth in this Agreement, until such appointment ends in accordance with this Section 1.2 (the “Term”). Chairman’s start date as Chairman of the Board shall be as of
August 13, 2013. 
 (a) Resignation by Chairman. The Chairman may terminate this Agreement and resign from his position as
Chairman of the Board at any time, for any reason or no reason, with or without Cause, by providing the Board 30 days advance written notice. Thereafter, all obligations of the Company under this Agreement shall cease except that Chairman will be
entitled to Chairman Compensation earned through the effective date of resignation as well as the separation compensation and benefits provided in Sections 4 and 5 below, if applicable. 

(b) Removal by the Board Without Cause. The Board may terminate this Agreement and remove the Chairman from his position as Chairman of
the Board at any time, for any reason or no reason, with or without Cause (as defined below), by providing Chairman 

  
 1 

 
with 30 days advance written notice. Thereafter, all obligations of the Company under this Agreement shall cease except that Chairman will be entitled to Chairman Compensation earned through the
effective date of resignation as well as the separation compensation and benefits provided in Sections 4 and 5 below, if applicable. 

(c) Removal by the Board For Cause. The Board may terminate this Agreement and remove the Chairman from his position as Chairman of the
Board at any time for Cause (as defined below), without prior notice (unless specifically provided for to the contrary), without liability to the Chairman except for Chairman Compensation earned through the effective date of such termination date as
well as the as the separation compensation and benefits provided in Sections 4 and 5 below, if applicable. 
 (d) Removal Due to Death or
Complete Disability. If Chairman dies or suffers a Complete Disability (as defined below) during the Term, Chairman’s service as Chairman of the Board shall automatically terminate upon such death or Complete Disability. Thereafter, all
obligations of the Company under this Agreement shall cease except that Chairman or Chairman’s heirs will be entitled to Chairman Compensation earned through the effective date of resignation as well as the separation compensation and benefits
provided in Sections 4 and 5 below, if applicable. 
 1.3 Duties. The Chairman shall do and perform all services, acts or things
necessary or advisable to manage and conduct the business of the Board and which are normally associated with the position of Chairman of the Board of a public company, consistent with the Bylaws of the Company and as required by the Board. As
Chairman of the Board, Chairman shall lead all meetings of the Board and all meetings of the stockholders of the Company, as well as set the agenda for all meetings of the Board and the stockholders. 

1.4 Policies and Practices. The retention of Chairman as Chairman of the Board shall be further governed by the policies and practices
established from time to time by the Company and the Board. In the event of any inconsistencies or conflict between this Agreement and such policies and practices, the terms and conditions of this Agreement shall control. 

1.5 Location. The Chairman will attend and participate in meetings via teleconference, videoconference, or in person, and will consult
with other members of the Board regularly and as necessary via telephone, electronic mail, or other forms of correspondence. The Chairman shall perform the services as Chairman pursuant to this Agreement at the Company’s offices, located in El
Cajon, California, only when reasonably requested by the Company. 
 2. LOYAL AND CONSCIENTIOUS
PERFORMANCE. 
 While serving as Chairman of the Board hereunder, the Chairman will devote no less than one day each week
to the performance of Chairman’s duties, and will not take any action that would directly or indirectly promote any competitor or impair the Company’s interests. Subject to the foregoing, while acting as Chairman of the Board, the Chairman
may engage in other business or charitable activities to the extent that they do not interfere or create a conflict with the fiduciary obligations of the Chairman of the Board owed to the Company. The Chairman will be free to represent or perform
services for other persons while acting solely as 

  
 2 

 
the Chairman of the Board. However, the Chairman agrees that Chairman does not presently perform and will not perform during the term of Agreement, consulting or other services for companies
whose businesses are or would be, in any material way, competitive with the Company, without the Board’s prior approval. 
 3.
COMPENSATION OF THE CHAIRMAN. 
 3.1 Chairman Compensation. Commencing
as of August 13, 2013 and through November 13, 2013, the Company shall pay the Chairman $41,666.67 per month for services as the Chairman of the Board, payable on a monthly basis in accordance with the Company’s policy for payments to
Board members; and commencing on November 14, 2013 through the remainder of the Term, the Company shall pay the Chairman $12,500 per month for services as the Chairman of the Board, payable on a quarterly basis in accordance with the
Company’s policy for payments to Board Members (collectively, “Chairman Compensation”). Such Chairman Compensation shall be prorated for any partial year of service on the basis of a 365-day fiscal year. 

3.2 Annual Discretionary Bonuses. In addition to the Chairman’s Chairman Compensation, the Chairman will be eligible to receive
annual and periodic bonuses in such amounts and upon such terms as may be determined from time to time by the Board. 
 3.3 Reductions to
Compensation. The Chairman Compensation may be reduced only by mutual agreement of the Chairman and the Company. 
 3.4 Withholding
Taxes. Chairman understands and agrees that he is an independent contractor and not an employee of the Company. As a result, the Company will not make deductions for taxes from any amounts payable to Chairman as a result of his Services to the
Company or as a result of the vesting or settlement of any equity-based awards (except as otherwise required by applicable law or regulation). Any taxes imposed on the Chairman due to Services to the Company (including upon the issuance, vesting and
settlement of any equity-based awards) will be the sole responsibility of the Chairman. 
 3.5 Stock Awards.  

(a) Restricted Stock Unit Grant. As an inducement to Chairman’s agreement to serve as Chairman of the Board, Chairman will be
granted an award consisting of two million eight hundred thousand (2,800,000) Restricted Stock Units. The terms and conditions for the Restricted Stock Units are contained in the Restricted Stock Units Agreement attached hereto as Exhibit
A and incorporated herein by reference. 
 (b) Additional Stock Awards. In addition, the Company may grant the Chairman
additional stock awards at such times and on such terms as may be decided from time to time by the Board or its Compensation Committee, in its sole discretion. 

3.6 Expenses.  

(a) Ordinary Business Expenses. The Chairman is authorized to incur reasonable expenses in the conduct of his Services to the Company
as Chairman of the Board, 

  
 3 

 
including expenses for meals, travel, and other similar items. The Company shall prepay or reimburse the Chairman for all such expenses. 

(b) Expense Prepayment and Reimbursement Procedures. All prepayments and reimbursements of the Chairman’s expenses pursuant to
this Section 3.6 are subject to the Chairman’s provision of invoices, an itemized accounting or other appropriate documentation evidencing such expenses no later than three (3) months following the date such expenses were incurred.
Any reimbursement payment shall be made by the Company as soon as practicable following its receipt of such documentation, but in no event later than the end of the Chairman’s taxable year following the year in which the Chairman incurred such
expenses. 
 3.7 Indemnification. Company shall indemnify the Chairman to the fullest extent permitted by the Company’s Bylaws
and applicable Delaware law as set forth in the Indemnification Agreement attached hereto as Exhibit B and incorporated herein by reference, which shall be construed to provide the broadest permissible indemnification rights to the Chairman.

 3.8 Insurance. The Company shall maintain an insurance policy or policies providing officers and directors’ liability
insurance and shall include the Chairman as an insured under the officers and directors liability insurance policy, with coverage to be in an amount determined by the Board, though in no event less than the amount in effect on the Effective Date.
Said coverage shall also specifically encompass all prior acts regarding the Company and shall provide coverage to Chairman after termination of this Agreement for all time periods prior to termination of the Agreement. 

4. TERMINATION BENEFITS. 

4.1 Termination By Chairman. If the Chairman’s resigns from his position as Chairman of the Board without Good Reason (as defined
below), then the Company shall pay to the Chairman or the Chairman’s heirs the Chairman Compensation, any bonus awarded under Section 3.2 not previously paid, each as earned through the date of resignation at the rate then in effect, and
the Company shall thereafter have no further obligations to the Chairman and/or the Chairman’s heirs under this Agreement, except as expressly otherwise provided in Sections 4 and 5. If the Chairman’s service as Chairman of the Board
terminates due to the Chairman’s death or Complete Disability (as defined below), the Company shall provide to the Chairman (or the Chairman’s beneficiaries, as applicable) the separation benefits described in Section 4.2 below. 

4.2 Benefits Upon Termination Without Cause or for Good Reason. In the event the Board removes the Chairman from his position as
Chairman of the Board without Cause (as defined below) or the Chairman resigns for Good Reason (as defined below), then subject to the Chairman’s delivery to the Company of a Release and Waiver of Claims in the form attached hereto as
Exhibit C no later than forty-five (45) days following the Termination Date, the Company shall provide the Chairman with the following separation benefits after the Release Effective Date as defined in Exhibit C: 

  
 4 

 (a) The Chairman shall be entitled to separation pay in the form of continued payment of
the annual Chairman Compensation then in effect on the termination date for a period of twelve (12) months. Such continued separation payments shall be paid bi-monthly commencing upon the Release Effective Date; provided, however, that if the
period between the termination date and thirty (30) days after the termination date spans two tax years, the separation payments will always begin starting with the month of the second tax year. 

(b) The Chairman shall have rights in connection with Restricted Stock Units as set out in Exhibit A. 

(c) Notwithstanding any contrary terms of any stock option grants, any outstanding vested stock options held by the Chairman at the
date of such termination shall continue to be exercisable for a period of up to ninety (90) days following such termination, but in no event beyond the maximum permitted expiration date of such stock options. 

4.3 Definitions. For purposes of this Agreement, the following terms shall have the following meanings: 

(a) Good Reason. “Good Reason” for the Chairman to resign from his position as Chairman of the Board shall mean
the occurrence of any of the following events without the Chairman’s consent; provided however, that any resignation by the Chairman due to any of the following conditions shall only be deemed for Good Reason if: (i) the Chairman gives the
Board written notice of the intent to resign for Good Reason within ninety (90) days following the first occurrence of the condition(s) that the Chairman believes constitutes Good Reason, which notice shall describe such condition(s);
(ii) the Company fails to remedy, if remediable, such condition(s) within thirty (30) days following receipt of the written notice (the “Cure Period”) of such condition(s) from the Chairman; and (iii) the
Chairman actually resigns his employment within the first ninety (90) days after expiration of the Cure Period: (A) a material reduction by the Board of the Chairman’s annual Chairman Compensation as initially set forth herein or as
the same may be increased from time to time (unless reductions comparable in amount and duration are concurrently made for all other non-employee members of the Board); (B) a material reduction by Board of the Chairman’s authority, duties
or responsibilities or the assignment to the Chairman of any duties substantially inconsistent with the Chairman’s position, duties and responsibilities with the Company; or (C) a material breach by the Company of this Agreement or any
other agreement between the Company and Chairman. 
 (b) Cause. “Cause” shall mean that one or more of the
following has occurred: (i) the Chairman has been convicted for, or entered a plea of guilty or nolo contendere to, a felony crime involving fraud, dishonesty or violence (under the laws of the United States or any relevant state, in the
circumstances, thereof); (ii) the Chairman has intentionally or willfully engaged in material acts of fraud, dishonesty or gross misconduct that have a material adverse effect on the Company; (iii) the willful failure or refusal of
Chairman to carry out the lawful directions of the Board (determined by a majority of the then serving directors other than the Chairman) or the duties assigned to Chairman by the Board; or (iv) any material violation by the Chairman of any
written Company policy applicable to the Chairman; or (v) any material breach by the Chairman of any provision of this Agreement or any other Agreement between the Company and Chairman. Notwithstanding the foregoing, the termination of
Chairman’s services 

  
 5 

 
as Chairman of the Board shall not constitute termination for Cause, unless the Company first provides Chairman with written notice of the basis for the termination and, with respect to a
termination based on clauses (iii), (iv) and/or (v) above, a fifteen (15) day period to correct the breach or failure or refusal. During this 15 day notice period, the Chairman will be afforded the opportunity to make a presentation
to the Board regarding the matters referred to in the notice. 
 (c) Complete Disability. “Complete
Disability” shall mean the inability of the Chairman to perform his duties under this Agreement because the Chairman has become permanently disabled within the meaning of any policy of disability income insurance covering employees of
the Company then in force. In the event the Company has no policy of disability income insurance covering employees of the Company in force when the Chairman becomes disabled, the term Complete Disability shall mean the inability of the Chairman to
perform his duties under this Agreement by reason of any incapacity, physical or mental, which the Board (based on a majority vote of the directors then serving other than the Chairman), based upon medical advice or an opinion provided by a licensed
physician acceptable to the Board, determines to have incapacitated the Chairman from satisfactorily performing the Chairman’s usual services for the Company for a period of at least one hundred twenty (120) consecutive days during any
12-month period. 
 5. CHANGE OF CONTROL TERMINATION BENEFITS. 

5.1 Change of Control Benefits. In the event that within twelve (12) months following a Change of Control either: (A) the
Chairman is removed from his position as Chairman of the Board without Cause or (B) a condition arises that triggers the Chairman’s right to give notice of resignation for Good Reason (as defined above), and the Chairman actually resigns
for Good Reason, within the applicable time periods thereafter as provided under Section 4.3, in either case subject to fulfillment of the Release and Waiver requirements of Section 4.2, the Company shall provide the Executive with the
following separation benefits: (a) a single lump sum payment equal to two hundred percent (200%) of Chairman’s annual Chairman Compensation then in effect, to be paid within thirty (30) days after the Release Effective Date; and
(b) the Chairman shall have the right to exercise stock options as provided for above in Section 4.2(c) above; and (c) the Chairman shall have rights in connection with Restricted Stock Units as set out in Exhibit A. 

5.2 Change of Control Defined. “Change of Control” means the occurrence of any of the following events: (i) the
closing of the sale, transfer or other disposition of all or substantially all of the Company’s assets or the exclusive license of substantially all of the intellectual property of the Company material to the business of the Company resulting
in the Company being unable to continue its business as in effect prior to such license; provided, however, that a mortgage, pledge or grant of a security interest to a bona fide lender shall not by itself constitute a Change of Control;
(ii) the consummation of a merger or consolidation of the Company with or into another entity in which the stockholders of the Company exchange their shares of capital stock of the Company for cash, stock, property or other consideration
(except one in which the stockholders of the Company as constituted immediately prior to such transaction continue to hold after the transaction at least 50% of the voting power of the capital stock of the Company or the surviving or acquiring
entity or parent entity of the surviving or acquiring entity); (iii) any “person,” as such term is used in Sections 13(d) and 14(d) of the 

  
 6 

 
Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) (other than (a) a trustee or other fiduciary holding securities under an
employee benefit plan of the Company, (b) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company or (c) any current beneficial
stockholder or group, as defined by Rule 13d-5 of the Exchange Act, including the heirs, assigns and successors thereof, of beneficial ownership, within the meaning of Rule 13d 3 of the Exchange Act, of securities possessing more than 20% of the
total combined voting power of the Company’s outstanding securities) hereafter becomes the “beneficial owner,” as defined in Rule 13d 3 of the Exchange Act, directly or indirectly, of securities of the Company representing 35% or more
of the total combined voting power represented by the Company’s then outstanding voting securities; or (iv) individuals who, as of sixty (60) days after the Effective Date of this Agreement are members of the Board (the
“Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended
by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Agreement, be considered as a member of the Incumbent Board; provided further, however, that a transaction under clauses
(ii) or (iii) above shall not constitute a Change of Control: (A) if its primary purpose is to change the state of the Company’s incorporation, (B) if its primary purpose is to create a holding company that will be owned in
substantially the same proportions by the persons who held the Company’s securities immediately prior to such transaction, or (C) if it is a bona fide equity financing in which the Company is the surviving corporation. 

6. TAX TREATMENT. 

6.1 Notwithstanding anything contained in this Agreement to the contrary, to the extent that any payment or benefit (within the meaning
of Section 280G(b)(2) of the Code) to the Chairman or for the Chairman’s benefit, paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise in connection with, or arising out of, the
Chairman’s Services to the Company or a Change of Control (a “Payment” or “Payments”), would be subject to the excise tax imposed under Code Section 4999, or any interest or penalties are
incurred by the Chairman with respect to such excise tax (such excise tax, together with any such interest and penalties, are hereinafter collectively referred to as the “Excise Tax”), the Payments shall be reduced (but not
below zero) if and to the extent that a reduction in the Payments would result in the Chairman retaining a larger amount, on an after-tax basis (taking into account federal, state and local income taxes and the Excise Tax), than if the Chairman
received all of the Payments (any such reduced amount is hereinafter referred to as the “Limited Payment Amount”). The Company shall reduce or eliminate the Payments by (i) first reducing or eliminating those payments
which are payable in cash and then (ii) by reducing or eliminating acceleration of stock options, in reverse order beginning with the options that but for the acceleration would have vested the farthest in time from the Determination (as
hereinafter defined). 
 6.2 An initial determination as to whether the Payments shall be reduced to the Limited Payment Amount and
the amount of such Limited Payment Amount shall be made, at the Company’s expense, by the accounting firm that is the Company’s independent accounting firm as of the date of the Change of Control (the “Accounting
Firm”). The Accounting Firm 

  
 7 

 
shall provide its determination (the “Determination”), together with detailed supporting calculations and documentation, to the Company and the Chairman within five
(5) days of the Termination Date, if applicable, or such other time as requested by the Company or by the Chairman (provided the Chairman reasonably believes that any of the Payments may be subject to the Excise Tax) and, if the Accounting Firm
determines that no Excise Tax is payable by the Chairman with respect to a Payment or Payments, it shall furnish the Chairman with an opinion reasonably acceptable to the Chairman that no Excise Tax will be imposed with respect to any such Payment
or Payments. Within ten (10) days of the delivery of the Determination to the Chairman, the Chairman shall have the right to dispute the Determination (the “Dispute”). If there is no Dispute, the Determination shall be
binding, final and conclusive upon the Company and the Chairman, subject to the application of Section 6.3 below. 
 6.3 As a
result of the uncertainty in the application of Sections 4999 and 280G of the Code, it is possible that the Payments actually made to, or provided for the benefit of, the Chairman either will be greater (an “Excess Payment”)
or less (an “Underpayment”) than the proper Limited Payment Amount provided for in Section 6.1. 
 (a)
If it is established, pursuant to a final and conclusive determination of a court or the Internal Revenue Service (the “IRS”) that an Excess Payment has been made, the Chairman must repay such Excess Payment to the
Company; provided, that no Excess Payment will be repaid by the Chairman to the Company unless, and only to the extent that, the repayment would either reduce the amount on which the Chairman is subject to tax under Code Section 4999 or
generate a refund of tax imposed under Code Section 4999. 
 (b) In the event that it is determined by (i) the Accounting
Firm, the Company (which shall include the position taken by the Company, or together with its consolidated group, on its federal income tax return) or the IRS, or (ii) pursuant to a determination by a court, or (iii) upon the resolution
to the Chairman’s satisfaction of the Dispute, that an Underpayment has occurred, the Company shall pay an amount equal to the Underpayment to the Chairman within ten (10) days of such determination or resolution, together with interest on
such amount at the applicable federal rate under Code Section 7872(f)(2) from the date such amount would have been paid to the Chairman until the date of payment. 

7. APPLICATION OF INTERNAL REVENUE CODE SECTION 409A.
 
 7.1 Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement (the
“Severance Benefits”) that constitute “deferred compensation” within the meaning of Section 409A of the Code and the regulations and other guidance thereunder or any state law of similar effect (collectively
“Section 409A”) and that are not exempt from Section 409A shall not commence in connection with the Chairman’s termination of employment unless and until the Chairman has also incurred a “separation from
service” (as such term is defined in Treasury Regulation Section 1.409A-1(h) (“Separation From Service”). For purposes of Section 409A, each payment provided in Section 4 will be treated as a separate
payment. 
 7.2 For the avoidance of doubt, it is intended that payments of the Severance Benefits set forth in this Agreement
satisfy, to the greatest extent possible, the exemptions from the 

  
 8 

 
application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4) [short-term deferral], 1.409A-1(b)(5) [stock options] and 1.409A-1(b)(9) [separation pay]. However, if
the Company (or, if applicable, the successor entity thereto) determines that a Severance Benefit constitutes “deferred compensation” under Section 409A and the Chairman is, on the Chairman’s Separation From Service, a
“specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code and the Treasury regulations, then, solely to the extent necessary to avoid the incurrence of the
adverse personal tax consequences under Section 409A, the timing of the Severance Benefit payment shall be delayed until the earlier to occur of: (i) the date that is six months and one day after the Chairman’s Separation From
Service”) or (ii) the date of the Chairman’s death (such applicable date, the “Specified Employee Initial Payment Date”). On the Specified Employee Initial Payment Date, the Company (or the successor entity
thereto, as applicable) shall pay to the Chairman a lump sum amount equal to the Severance Benefit payment that the Chairman would otherwise have received through the Specified Employee Initial Payment Date if the payment of the Severance Benefits
had not been so delayed pursuant to this Section. 
 7.3 The Severance Benefits are intended to qualify for an exemption from
application of Section 409A or to comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and this Agreement shall be interpreted accordingly. 

8. CONFIDENTIAL AND PROPRIETARY INFORMATION; NONSOLICIATION. 

As a condition of continued employment the Chairman agrees to execute and abide by the Proprietary Information and Inventions Agreement in the
form attached hereto as Exhibit D. 
 9. ASSIGNMENT AND BINDING EFFECT. 

This Agreement shall be binding upon and inure to the benefit of the Chairman and the Chairman’s heirs, executors, personal
representatives, assigns, administrators and legal representatives. Because of the unique and personal nature of the Chairman’s duties under this Agreement, neither this Agreement nor any rights or obligations under this Agreement shall be
assignable by the Chairman. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives. As a condition to entering into an acquisition agreement, the Company will require any
acquiror or successor to assume its obligations under this Agreement. 
 10. CHOICE OF LAW. 

This Agreement will be governed by the laws of the State of California, without giving effect to the conflict of law principles thereof. For
purposes of litigating any dispute that arises under this Agreement, the parties hereby submit to and consent to the jurisdiction of the State of California, and agree that such litigation will be conducted in the courts of San Diego County,
California, or the federal courts for the United States for the Southern District of California, and no other courts, where this Agreement is made and/or to be performed. 

  
 9 

 11. INTEGRATION. 

This Agreement, including all Exhibits attached hereto, contains the complete, final and exclusive agreement of the Parties relating to the
terms and conditions of the Chairman’s employment and the termination of the Chairman’s employment, and supersedes all prior and contemporaneous oral and written employment agreements or arrangements between the Parties and between the
Chairman and the Company. 
 12. AMENDMENT. 

This Agreement cannot be amended or modified except by a written agreement signed by the Chairman and the Board representative specifically
authorized by the Board to execute any such amendment or modification to this Agreement on behalf of the Company. 
 13. SURVIVAL
OF CERTAIN PROVISIONS. 
 Sections 1, 3.4, 3.7, 4 through 17, 19 and 21 shall survive the
termination of this Agreement. 
 14. WAIVER. 

No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the Party
against whom the waiver is claimed, and any waiver of any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach. 

15. SEVERABILITY. 
 The
finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the
authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or provision which most accurately represents the Parties’ intention with respect to the invalid or unenforceable term or provision.
Any such invalid or unenforceable term or provision shall be revised to the minimum extent necessary to make any such term or provision valid or enforceable in accordance with the Parties’ intentions with respect to such term or provision. 

16. INTERPRETATION; CONSTRUCTION. 

The headings set forth in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement. The
Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of this Agreement. 
 17. REPRESENTATIONS AND WARRANTIES.

 The Chairman represents and warrants that the Chairman is not restricted or prohibited, contractually or otherwise, from entering into
and performing each of the terms and covenants contained in this Agreement, and that Chairman’s execution and performance of this Agreement 

  
 10 

 
will not violate or breach any other agreements between the Chairman and any other person or entity. 

18. COUNTERPARTS. 
 This
Agreement may be executed in two counterparts, each of which shall be deemed an original, both of which together shall constitute one and the same instrument. In the event that any signature is delivered by fax or by e-mail delivery of a
“.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof. 
 19. ADVERTISING WAIVER. 

During the Term the Chairman agrees to permit the Company and/or its affiliates, and persons or other organizations authorized by the Company
and/or its affiliates, to use, publish and distribute advertising or sales promotional literature concerning the products and/or services of the Company and/or its affiliates, or the machinery and equipment used in the provision thereof, in which
the Chairman’s name and/or pictures of the Chairman taken in the course of the Chairman’s provision of services to the Company and/or its affiliates, appear. The Chairman hereby waives and releases any claim or right the Chairman may
otherwise have arising out of such use, publication or distribution. 
 20. SPECIFIC ENFORCEMENT. 

If necessary and where appropriate, the Company shall have the right to enforce the provisions of the Proprietary Information and Inventions
Agreement by injunction, specific performance or other equitable relief without bond and without prejudice to any other rights and remedies the Company may have for a breach of such Exhibits to this Agreement. 

21. NOTICE. 
 21.1 Method and
Delivery. All notices, requests and demands hereunder shall be in writing and delivered by hand, by Electronic Transmission, by mail, or by recognized commercial overnight delivery service (such as Federal Express, UPS, or DHL), and shall be
deemed given (a) if by hand delivery, upon such delivery; (b) if by Electronic Transmission, upon confirmation of receipt of same; (c) if by mail, forty-eight (48) hours after deposit in
the United States mail, first class, registered or certified mail, postage prepaid; or, (d) if by recognized commercial overnight delivery service, upon such delivery. 

21.2 Consent to Electronic Transmissions. Each Party hereby expressly consents to the use of Electronic Transmissions for
communications and notices under this Agreement. For purposes of this Agreement, “Electronic Transmissions” means a communication (i) delivered by facsimile telecommunication or electronic mail when directed to the facsimile number or
electronic mail address, respectively, for that recipient on record with the sending Party; and, (ii) that creates a record that is capable of retention, retrieval, and review, and that may thereafter be rendered into clearly legible tangible
form. 

  
 11 

 IN WITNESS WHEREOF, the Parties have executed this Agreement with an Effective Date of the 23rd
day of October 2013. 
  

					
	CHAIRMAN:	 		 	 COMPANY:
  

Pure Bioscience, Inc.

			
	/S/ DAVE PFANZELTER	 	  
	 	  

	DAVE PFANZELTER	 		 	
	  
	 	  
	 	/S/ PETER WULFF
			
		 		 	PETER WULFF, Chief Operating Officer

  
 12 

 EXHIBIT A 

RSU AGREEMENT 
  

 EXHIBIT B 

INDEMNIFICATION AGREEMENT 
  

 EXHIBIT C 

RELEASE AND WAIVER OF CLAIMS 

In consideration of the payments and other benefits set forth in the Chairman Agreement, dated October 23, 2013 (the “
Agreement”), to which this form is attached, I, DAVE PFANZELTER, hereby furnish PURE BIOSCIENCE, INC. (the “Company”), with the following release and waiver
(“Release and Waiver”). 
 In exchange for the consideration provided to me by the Agreement that I am not otherwise
entitled to receive, I hereby generally and completely release the Company and its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, Affiliates, and assigns
from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring relating to my services to the Company or the termination thereof prior to my
signing this Release and Waiver. Notwithstanding the foregoing, this Release and Waiver, shall not release or waive my rights: to indemnification under the articles and Bylaws of the Company or applicable law, including without limitations,
California Labor Code Sections 2800 and 2802 and the Indemnification Agreement (Exhibit B); to payments under Sections 4 and 5 of my Chairman Agreement; under any provision of the Chairman Agreement that survives the termination of that agreement;
under the California Workers’ Compensation Act; under any option, restricted share or other agreement concerning any equity interest in the Company; as a shareholder of the Company or any other right that is not waivable under applicable law.

 I also acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A
general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the
debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to any claims I may have against the Company. 

This Release and Waiver constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with
regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein. This Release and Waiver may only be modified by a writing signed by both me and a duly authorized officer of
the Company. 
  

							
	Date:
                                        
	 		 	By: 	 	 
		 		 		 	DAVE PFANZELTER

 EXHIBIT D 

PURE BIOSCIENCE, INC. 

PROPRIETARY INFORMATION 

AND INVENTIONS AGREEMENT 

In consideration of my Chairman Agreement with PURE BIOSCIENCE, INC. (the “Company”),
and the compensation now and hereafter paid to me, I hereby agree as follows, effective as of August 13, 2013: 

 

 1. NONDISCLOSURE 

1.1 Recognition of Company’s Rights; Nondisclosure. At all times during my services to the Company and thereafter, I will hold in
strictest confidence and will not disclose, use, lecture upon or publish any of the Company’s and/or its Affiliates’ Proprietary Information (defined below), except as such disclosure, use or publication may be required in connection with
my work for the Company, or unless an officer of the Company expressly authorizes such in writing. I will obtain Company’s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that
relates to my work at Company and/or incorporates any Proprietary Information. I hereby assign to the Company any rights I may have or acquire in such Proprietary Information and recognize that all Proprietary Information shall be the sole property
of the Company and its assigns. For purposes of this Agreement, “Affiliate” means, with respect to any specific entity, any other entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by or
is under common control with such specified entity. 
 1.2 Proprietary Information. The term “Proprietary
Information” shall mean any and all confidential and/or proprietary knowledge, data or information of the Company and/or its Affiliates. By way of illustration but not limitation, “Proprietary Information” includes
(a) trade secrets, inventions, mask works, ideas, processes, formulas, source and object codes, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques (hereinafter collectively
referred to as “Inventions”); and (b) information regarding plans for research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs,
suppliers and customers; and (c) information regarding the skills and compensation of other employees of the

 
Company and/or its Affiliates. Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is generally known in the trade or industry, which is
not gained as result of a breach of this Agreement, and my own, skill, knowledge, know-how and experience to whatever extent and in whichever way I wish. 

1.3 Third Party Information. I understand, in addition, that the Company has received and in the future will receive from third
parties confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the
term of my services to the Company and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for the
Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an officer of the Company in writing. 

1.4 No Improper Use of Information of Prior Employers and Others. During my services to the Company I will not improperly use or
disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of the Company any unpublished documents or any
property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person. I will use in the performance of my duties only information which is
generally known and used by persons with training and experience comparable to my own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company.

 

  
 1. 

 2. ASSIGNMENT OF INVENTIONS. 

2.1 Proprietary Rights. The term “Proprietary Rights” shall mean all trade secret, patent, copyright, mask work and
other intellectual property rights throughout the world. 
 2.2 Prior Inventions. Inventions, if any, patented or unpatented, which
I made prior to the commencement of my services to the Company are excluded from the scope of this Agreement. To preclude any possible uncertainty, I have set forth on Exhibit B (Previous Inventions) attached hereto a complete list of
all Inventions that I have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of my services to the Company, that I consider to be my
property or the property of third parties and that I wish to have excluded from the scope of this Agreement (collectively referred to as “Prior Inventions”). If disclosure of any such Prior Invention would cause me to violate any
prior confidentiality agreement, I understand that I am not to list such Prior Inventions in Exhibit B but am only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full
disclosure as to such inventions has not been made for that reason. A space is provided on Exhibit B for such purpose. If no such disclosure is attached, I represent that there are no Prior Inventions. If, in the course of my employment with
the Company, I incorporate a Prior Invention into a Company product, process or machine, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license (with rights to sublicense through multiple
tiers of sublicensees) to make, have made, modify, use and sell such Prior Invention. Notwithstanding the foregoing, I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions without the
Company’s prior written consent. 
 2.3 Assignment of Inventions. Subject to Sections 2.4, and 2.6, I hereby assign and agree
to assign in the future (when any such Inventions or Proprietary Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to the Company all my right, title and interest in and to any and all Inventions (and all
Proprietary Rights with respect thereto) whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or learned by me, either alone or jointly with others, during the period of my services
to the Company. Inventions assigned

 
to the Company, or to a third party as directed by the Company pursuant to this Section 2, are hereinafter referred to as “Company Inventions.” 

2.4 Nonassignable Inventions. This Agreement does not apply to an Invention which qualifies fully as a nonassignable Invention under
Section 2870 of the California Labor Code (hereinafter “Section 2870”). I have reviewed the notification on Exhibit A (Limited Exclusion Notification) and agree that my signature acknowledges receipt of the
notification. 
 2.5 Obligation to Keep Company Informed. During the period of my services to the Company and for six
(6) months after the termination of my services to the Company, I will promptly disclose to the Company fully and in writing all Inventions authored, conceived or reduced to practice by me, either alone or jointly with others. In addition, I
will promptly disclose to the Company all patent applications filed by me or on my behalf within a year after termination of my services to the Company. At the time of each such disclosure, I will advise the Company in writing of any Inventions that
I believe fully qualify for protection under Section 2870; and I will at that time provide to the Company in writing all evidence necessary to substantiate that belief. The Company will keep in confidence and will not use for any purpose or
disclose to third parties without my consent any confidential information disclosed in writing to the Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the provisions of Section 2870. I will
preserve the confidentiality of any Invention that does not fully qualify for protection under Section 2870. 
 2.6 Government or
Third Party. I also agree to assign all my right, title and interest in and to any particular Company Invention to a third party, including without limitation the United States, as directed by the Company. 

2.7 Works for Hire. I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within
the scope of my services to the Company and which are protectable by copyright are “works made for hire,” pursuant to United States Copyright Act (17 U.S.C., Section 101). 

2.8 Enforcement of Proprietary Rights. I will assist the Company in every proper way to obtain, and from time to time enforce, United
States and foreign Proprietary Rights relating to 

 

 
Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as the Company may
reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Proprietary Rights to the
Company or its designee. My obligation to assist the Company with respect to Proprietary Rights relating to such Company Inventions in any and all countries shall continue beyond the termination of my services to the Company, but the Company shall
compensate me at a reasonable rate after my termination for the time actually spent by me at the Company’s request on such assistance. 
 In the event
the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in the preceding paragraph, I hereby irrevocably designate and appoint the Company and its duly
authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the
purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any
Proprietary Rights assigned hereunder to the Company. 
 3. RECORDS. I agree to keep and maintain adequate and current records (in the
form of notes, sketches, drawings and in any other form that may be required by the Company) of all Proprietary Information developed by me and all Inventions made by me during the period of my services to the Company, which records shall be
available to and remain the sole property of the Company at all times. 
 4. ADDITIONAL ACTIVITIES. I agree that during
the period of my services to the Company I will not, without the Company’s express written consent, engage in any employment or business activity which is competitive with, or would otherwise conflict with, my services to the Company. 

5. NO CONFLICTING OBLIGATION. I represent that my performance of all the terms of this Agreement and as a
director of the Company does not and will not breach any agreement to keep in

 
confidence information acquired by me in confidence or in trust prior to my retention by the Company. I have not entered into, and I agree I will not enter into, any agreement either written or
oral in conflict herewith. 
 6. RETURN OF COMPANY DOCUMENTS. When I leave the services
of the Company, I will deliver to the Company any and all drawings, notes, memoranda, specifications, devices, formulas, and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions, Third
Party Information or Proprietary Information of the Company. I further agree that any property situated on the Company’s premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject
to inspection by Company personnel at any time with or without notice. Prior to leaving, I will cooperate with the Company in completing and signing the Company’s termination statement. 

7. LEGAL AND EQUITABLE REMEDIES. Because my services are personal and unique and because I
may have access to and become acquainted with the Proprietary Information of the Company, the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without
bond and without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement. 
 8. NOTICES.
Any notices required or permitted hereunder shall be given to the appropriate party in accordance with Section 21 of the Chairman Agreement to which this Agreement is attached as Exhibit D 

9. NOTIFICATION OF NEW EMPLOYER. In the event that I leave the services of the Company, I
hereby consent to the notification of my new employer of my rights and obligations under this Agreement. 
 10. GENERAL
PROVISIONS. 
 10.1 Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by and
construed according to the laws of the State of California, as such laws are applied to agreements entered into and to be performed entirely within California between California residents. 

10.2 Severability. In case any one or more of the provisions contained in this Agreement

 

 
shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and
this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. If, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively
broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear. 

10.3 Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives
and will be for the benefit of the Company, its successors, and its assigns. 
 10.4 Survival. The provisions of this Agreement
shall survive the termination of my services to the Company and the assignment of this Agreement by the Company to any successor in interest or other assignee. 

10.5 Director. I agree and understand that nothing in this Agreement shall confer any right with respect to continuation of services
to the Company, nor shall it interfere in any way with my right or the Company’s right to terminate my services at any time, with or without cause. 

10.6 Waiver. No waiver by the Company of any breach of this Agreement shall be a waiver of any preceding or succeeding breach. No
waiver by the Company of any right under this Agreement shall be construed as a waiver of any other right. The Company shall not be required to give notice to enforce strict adherence to all terms of this Agreement. 

10.7 Entire Agreement. The obligations pursuant to Sections 1 and 2 of this Agreement shall apply to any time during which I was
previously retained, or am in the future retained, by the Company as a consultant if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement and Chairman Agreement to which it is attached as Exhibit D
and all other references in the Chairmn Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior discussions between us. No modification of or amendment to
this Agreement, nor any waiver of any rights under this

 
Agreement, will be effective unless in writing and signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope
of this Agreement. 
 This Agreement shall be effective as of the Effective Date, namely: August 13, 2013. 

I HAVE READ THIS AGREEMENT CAREFULLY AND
UNDERSTAND ITS TERMS. I HAVE COMPLETELY FILLED OUT EXHIBIT B TO THIS
AGREEMENT. 
 /s/ Dave Pfanzelter 

 
 (Signature) 

DAVE PFANZELTER 
  

(Printed Name) 
 ACCEPTED
AND AGREED TO: 
 PURE BIOSCIENCE, INC. 

			
		
	By: 	 	/s/ Peter Wulff
	Name: PETER WULFF
	Title: Chief Operating Officer

 
 

 EXHIBIT A 

LIMITED EXCLUSION NOTIFICATION 

THIS IS TO NOTIFY you in accordance with Section 2872 of the
California Labor Code that the foregoing Agreement between you and the Company does not require you to assign or offer to assign to the Company any invention that you developed entirely on your own time without using the Company’s equipment,
supplies, facilities or trade secret information except for those inventions that either: 
  

	 	1.	Relate at the time of conception or reduction to practice of the invention to the Company’s business, or actual or demonstrably anticipated research or development of the Company; 

 

	 	2.	Result from any work performed by you for the Company. 

 To the extent a provision in the
foregoing Agreement purports to require you to assign an invention otherwise excluded from the preceding paragraph, the provision is against the public policy of this state and is unenforceable. 

This limited exclusion does not apply to any patent or invention covered by a contract between the Company and the United States or any of its
agencies requiring full title to such patent or invention to be in the United States. 
 I ACKNOWLEDGE
RECEIPT of a copy of this notification. 
  

			
	By: 	 	/s/ Dave Pfanzelter
		 	(PRINTED NAME OF SERVICE PROVIDER)
	
	Date: October 23, 2013

  

	
	WITNESSED BY:
	
	/s/ Peter Wulff
	(PRINTED NAME OF REPRESENTATIVE)

  
 1. 

 EXHIBIT B 

 

					
	TO:	  	PURE BIOSCIENCE, INC.	  	
			
	FROM:	  	  
	  	
			
	DATE:	  	  
	  	
			
	SUBJECT:	  	Previous Inventions	  	

 1. Except as listed in Section 2 below, the following is a complete list of all inventions or
improvements relevant to the subject matter of my services to PURE BIOSCIENCE, INC. (the “Company”) that have been made or conceived or first reduced to practice by me alone or jointly with
others prior to my engagement by the Company: 
  

	 	 ̈	No inventions or improvements. 

  

	 	 ̈	See below: 

  
  

 
  

 
  

 

	 ̈	Additional sheets attached. 

 2. Due to a prior confidentiality agreement, I cannot
complete the disclosure under Section 1 above with respect to inventions or improvements generally listed below, the proprietary rights and duty of confidentiality with respect to which I owe to the following party(ies). 

 

							
	 	 	Invention or Improvement	    	Party(ies)	    	Relationship
				
	1.	 	  
	    	  
	    	  

				
	2.	 	  
	    	  
	    	  

				
	3.	 	  
	    	  
	    	  

  

	 ̈	Additional sheets attached.EX-10.36

 Exhibit 10.36 

PURE Bioscience, Inc. 

RESTRICTED STOCK UNITS AGREEMENT 

(Director) 
 THIS
RESTRICTED STOCK UNITS AGREEMENT (the “Agreement”) is made and entered into as of the 23rd day of October, 2013 (the “Grant Date”), by and between PURE BIOSCIENCE, INC.,
a Delaware corporation, and                  (the “Grantee”), a director on the Company’s Board of Directors. The
Company has granted to the Grantee an award (the “Award”) consisting of 200,000 Restricted Stock Units (the “Total Number of Units”), subject to the terms and conditions of
this Agreement. Each Unit represents a right to receive upon settlement one (1) share of Stock. The Award has not been granted pursuant to any compensatory, bonus, or similar plan maintained or otherwise sponsored by the Company (collectively,
the “Plan”), and the shares of Stock that may become issuable upon settlement the Units shall not reduce the number of shares of Stock available for issuance under any Plan. 

1. DEFINITIONS AND CONSTRUCTION. 

1.1 Definitions. Capitalized terms used herein shall have the following meanings: 

(a) “Board” means the Board of Directors of the Company. If one or more committees of the Board of
Directors have been appointed by the Board to administer this Agreement, “Board” also means such committee(s). 

(b) “Cause” means that one or more of the following has occurred: (i) the Grantee has been
convicted for, or entered a plea of guilty or nolo contendere to, a felony crime involving fraud, dishonesty or violence (under the laws of the United States or any relevant state, in the circumstances, thereof); (ii) the Grantee has
intentionally or willfully engaged in material acts of fraud, dishonesty or gross misconduct that have a material adverse effect on the Company; (iii) the willful failure or refusal of the Grantee to carry out the lawful directions of the Board
(determined by a majority of the then serving directors other than the Chairman) or the duties assigned to the Grantee by the Board; (iv) any material violation of any written Company policy applicable to the Grantee; or (v) any material
breach by Grantee of any provision of this Agreement or any other agreement between the Company and Grantee. Notwithstanding the foregoing, the removal of Grantee from the Board shall not constitute a removal for Cause, unless the Company first
provides Grantee with written notice of the basis for the termination and, with respect to a termination based on clauses (iii), (iv) and/or (v) above, a fifteen (15) day period to correct the breach or failure or refusal. During this
15 day notice period, the Grantee will be afforded the opportunity to make a presentation to the Board regarding the matters referred to in the notice. 

(c) “Change in Control” means the occurrence of any of the following events: (i) the closing of the
sale, transfer or other disposition of all or substantially all of the Company’s assets or the exclusive license of substantially all of the intellectual property of the Company material to the business of the Company resulting in the Company
being unable to continue its business as in effect prior to such license; provided, however, that a mortgage, pledge or grant of a security interest to a bona fide lender shall not by itself constitute a Change of Control; (ii) the consummation
of a merger or consolidation of the Company with or into another entity in which the stockholders of the Company exchange their shares of capital stock of the Company for cash, stock, property or other consideration (except one in which the
stockholders of the Company as constituted immediately prior to such transaction continue to hold after the transaction at least 50% of the voting power of the capital stock of the Company or the surviving or acquiring entity or parent entity of the
surviving or acquiring entity); (iii) any “person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) (other
than (a) a trustee or other fiduciary holding securities under an employee benefit plan of the Company, (b) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their
ownership of stock of the Company or (c) any current beneficial stockholder or group, as 

  
 1 

 
defined by Rule 13d-5 of the Exchange Act, including the heirs, assigns and successors thereof, of beneficial ownership, within the meaning of Rule 13d 3 of the Exchange Act, of securities
possessing more than 20% of the total combined voting power of the Company’s outstanding securities) hereafter becomes the “beneficial owner,” as defined in Rule 13d 3 of the Exchange Act, directly or indirectly, of securities of the
Company representing 35% or more of the total combined voting power represented by the Company’s then outstanding voting securities; or (iv) individuals who, as of sixty (60) days after the Effective Date of this Agreement are members
of the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board
member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Agreement, be considered as a member of the Incumbent Board; provided further, however,
that a transaction under clauses (ii) or (iii) above shall not constitute a Change of Control: (A) if its primary purpose is to change the state of the Company’s incorporation, (B) if its primary purpose is to create a
holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately prior to such transaction, or (C) if it is a bona fide equity financing in which the Company is the
surviving corporation. 
 (d) “Code” means the Internal Revenue Code of 1986, as amended, and any
applicable regulations and administrative guidelines promulgated thereunder. 
 (e) “Company” means
PURE Bioscience, Inc., a Delaware corporation, and any successor thereto. 
 (f) “Complete
Disability” means the inability of the Grantee to perform his duties as a director on the Company’s Board and any applicable Board committees because the Grantee has become permanently disabled within the meaning of any
policy of disability income insurance covering employees of the Company then in force. In the event the Company has no policy of disability income insurance covering employees of the Company in force when the Grantee becomes disabled, the term
Complete Disability shall mean the inability of the Grantee to perform his duties under this Agreement by reason of any incapacity, physical or mental, which the Board (based on a majority vote of the directors then serving on the Board other than
the Grantee), based upon medical advice or an opinion provided by a licensed physician acceptable to the Board, determines to have incapacitated the Grantee from satisfactorily performing the Grantee’s usual services for the Company for a
period of at least one hundred twenty (120) consecutive days during any 12-month period. 
 (g) “Dividend Equivalent
Units” mean additional Restricted Stock Units credited pursuant to Section 2.3. 
 (h) “Exchange
Act” means the Securities Exchange Act of 1934, as amended. 
 (i) “Expiration
Date” means the seventh (7th) anniversary of the Grant Date. 
 (j) “Fair Market
Value” means as of any date, the value of a share of Stock or other property as determined by the Board, in its discretion, or by the Company, in its discretion, if such determination is expressly allocated to the Company herein,
subject to the following: 
 (i) If, on such date, the Stock is listed or quoted on a national or regional securities exchange or quotation
system, the Fair Market Value of a share of Stock shall be the closing price of a share of Stock as quoted on the national or regional securities exchange or quotation system constituting the primary market for the Stock, as reported in The Wall
Street Journal or such other source as the Company deems reliable. If the relevant date does not fall on a day on which the Stock has traded on such securities exchange or quotation system, the date on which the Fair Market Value shall be
established shall be the last day on which the Stock was so traded or quoted prior to the relevant date, or such other appropriate day as shall be determined by the Board, in its discretion. 

  
 2 

 (ii) If, on such date, the Stock is not listed or quoted on a national or regional securities
exchange or quotation system, the Fair Market Value of a share of Stock shall be as determined by the Board in good faith without regard to any restriction other than a restriction which, by its terms, will never lapse. 

(k) “Good Reason” means the occurrence of any of the following events without the Grantee’s consent; provided
however, that any resignation by the Grantee due to any of the following conditions shall only be deemed for Good Reason if: (i) the Grantee gives the Board written notice of the intent to resign for Good Reason within ninety (90) days
following the first occurrence of the condition(s) that the Grantee believes constitutes Good Reason, which notice shall describe such condition(s); (ii) the Board fails to remedy, if remediable, such condition(s) within thirty (30) days
following receipt of the written notice (the “Cure Period”) of such condition(s) from the Grantee; and (iii) the Grantee actually resigns from the Board within the first ninety (90) days after expiration of the Cure
Period: (A) a material reduction by the Board of the Grantee’s annual Board compensation as of the date of this Agreement or as the same may be increased from time to time (unless reductions comparable in amount and duration are
concurrently made for all other non-employee members of the Board) or (B) a material breach of this Agreement by the Company. 
 (l)
“Participating Company” means the Company and any subsidiary of the Company. 
 (m)
“Restricted Stock Unit” or “Unit” means a right to receive on the applicable Settlement Date and in accordance with this Agreement one (1) share of Stock, and includes
the Total Number of Units originally granted pursuant to this Agreement and the Dividend Equivalent Units credited pursuant to Section 2.3, as both may be adjusted from time to time pursuant to Section 7. 

(n) “Securities Act” means the Securities Act of 1933, as amended. 

(o) “Service” means the Grantee’s service to the Company as a director or consultant. The
Grantee’s Service shall not be deemed to have been interrupted or terminated if the Grantee takes any sick leave, or other bona fide leave of absence approved by the Company’s Board. 

(p) “Service Condition” means the condition to the vesting of the Award. The Service Condition is
satisfied based on the duration of the Grantee’s continuous Service from the Grant Date, as provided by Section 3.1. 
 (q)
“Settlement Date” means, for each Vested Unit, the same date the Service Condition is satisfied with respect to such Vested Unit. 

(r) “Stock” means the common stock of the Company, subject to adjustment as provided by Section 7.

 (s) “Trading Compliance Policy” means the written policy of the Company pertaining to the
purchase, sale, transfer or other disposition of the Company’s equity securities by directors, officers, employees or other service providers who may possess material, nonpublic information regarding the Company or its securities. 

(t) “Vested Unit” means a Unit that has vested in accordance with Section 3 and ceased to be
subject to the Company Reacquisition Right described in Section 4.1. 
 1.2 Construction. Captions and titles
contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of this Agreement. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the
singular. Use of the term “or” is not intended to be exclusive, unless the context clearly requires otherwise. 

  
 3 

 2. THE AWARD. 

2.1 Grant of Units. On the Grant Date, the Grantee shall acquire, subject to the provisions of this Agreement, the Total Number of
Units, subject to adjustment as provided in Section 7. Each Unit represents a right to receive one (1) share of Stock on the applicable Settlement Date and in accordance with this Agreement. 

2.2 No Monetary Payment Required. The Grantee is not required to make any monetary payment (other than applicable tax withholding, if
any) as a condition to receiving the Units or shares of Stock issued upon the vesting or settlement of the Units, the consideration for which shall be services to be rendered to a Participating Company or for its benefit. Notwithstanding the
foregoing, if required by applicable law, the Grantee shall furnish consideration in the form of cash or past services rendered to a Participating Company or for its benefit having a value not less than the par value of the shares of Stock issued
upon settlement of the Units. 
 2.3 Dividend Equivalent Units. On the date that the Company pays a cash dividend or other cash
distribution to holders of Stock generally, the Grantee shall be credited with a number of additional whole Dividend Equivalent Units determined by dividing (a) the product of (i) the dollar amount of the cash dividend or distribution paid
per share of Stock on such date and (ii) the total number of Units previously credited to the Grantee pursuant to this Agreement which have not been settled or forfeited pursuant to the Company Reacquisition Right (as defined below) as of such
date, by (b) the Fair Market Value per share of Stock on such date. Any resulting fractional Dividend Equivalent Unit shall be rounded to the nearest whole number. Such additional Dividend Equivalent Units shall be subject to the same terms and
conditions and shall be settled or forfeited in the same manner and at the same time as the Units originally subject to this Agreement with respect to which they have been credited. 

2.4 Termination of the Award. The Award shall terminate upon the first to occur of (a) the final settlement of all Vested Units in
accordance with Section 5 (including a final settlement upon the cessation of Grantee’s Services) or (b) the Expiration Date if settlement has not occurred on or before the Expiration Date. 

3. VESTING OF UNITS. 

3.1 Satisfaction of Service Condition. Except as provided by Section 3.2 below and subject to the Grantee’s continuous
Service through the applicable date set forth in the table below (each a “Service Date”), the Service Condition will be satisfied in accordance with the following schedule: 

 

					
	 Service Date
	  	Percentage of Units	 
	 The earlier of (i) January 15, 2015 or (ii) the Company’s annual meeting of stockholders held
in calendar 2015
	  	 	50	% 
	 The earlier of (i) January 15, 2016 or (ii) the Company’s annual meeting of stockholders held
in calendar 2016 
	  	 	50	% 

 3.2 Vesting Upon Change in Control or upon Removal Without Cause or Due to Death, Disability or Good
Reason. Upon the Occurrence of a Change in Control, the Service Condition will be satisfied with respect to one-hundred percent (100%) of the Total Number of Units effective as of the date of such Change in Control. If the Grantee’s
Service is involuntarily ceased by the Company for any reason other than Cause or the Grantee’s Service ends as a result of the Grantee’s death or Complete Disability or Grantee ends his Service for Good Reason, then the Service Condition
will be satisfied with respect to one-hundred percent (100%) of the Total Number of Units effective as of the date of such end of Service. If Grantee voluntarily resigns from providing Service to the Company, there shall be no acceleration of
the Service Condition. 

  
 4 

 3.3 Effect of the End of Service . Subject to the vesting provisions in Sections 3.1 and
3.2 above, upon the end of Grantee’s Service (whether by the Company or by Grantee and whether for Cause or for any or no reason), then: 

(a) all Units for which the Service Condition has not been satisfied as of the date of such end of Service shall be subject to
the Company Reacquisition Right (as defined in Section 4.1) immediately upon the end of Grantee’s Service; and 
 (b) all Units
for which the Service Condition has been satisfied as of the date of such end of Service (including as a result of Section 3.2) shall not be subject to the Company Reacquisition Right, but instead shall remain Vested Units. 

3.4 Federal Excise Tax Under Section 4999 of the Code. 

(a) Excess Parachute Payment. If any acceleration of vesting pursuant to the Award and any other payment or benefit
(collectively, the “Payments”) received or to be received by the Grantee would, but for this Section, subject the Grantee to any excise tax pursuant to Section 4999 of the Code or any similar or successor
provision (the “Excise Tax”) due to the characterization of such acceleration of vesting, payment or benefit as an “excess parachute payment” under Section 280G of the Code, then the aggregate
amount of the Payments will be either fully payable or reduced to the largest portion of the Payments that would result in no portion of the Payments (after reduction) being subject to the Excise Tax, whichever results in the Grantee receiving the
greatest amount of Payments, on an after-tax basis (accounting for federal, state, and local income taxes and the Excise Tax), even if some or all of the Payments are subject to the Excise Tax. Any reduction in the Payments required by this Section
will be made in the following order: (i) reduction of cash payments; (ii) reduction of accelerated vesting of equity awards other than stock options; (iii) reduction of accelerated vesting of stock options; and (iv) reduction of
other benefits paid or provided to the Grantee. In the event that acceleration of vesting of equity awards is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Grantee’s equity
awards. If two or more equity awards are granted on the same date, each award will be reduced on a pro-rata basis. 
 (b)
Determination by Tax Firm. No later than the date of the occurrence of any event that might reasonably be anticipated to result in an “excess parachute payment” to the Grantee, the Company shall request a determination in
writing by the professional firm engaged by the Company for general tax purposes, or, if the tax firm so engaged by the Company is serving as accountant or auditor for the acquiror, the Company will appoint a nationally recognized tax firm to make
the determinations required by this Section. (the “Tax Firm”). As soon as practicable thereafter, the Tax Firm shall determine and report to the Company and the Grantee the amount of such acceleration of
vesting, payments and benefits to be reduced, if any. For the purposes of such determination, the Tax Firm may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and the
Grantee shall furnish to the Tax Firm such information and documents as the Tax Firm may reasonably request in order to make its required determination. The Company shall bear all fees and expenses the Tax Firm charge in connection with its services
contemplated by this Section. 
 4. COMPANY REACQUISITION RIGHT.

 4.1 Grant of Company Reacquisition Right. In the event that the Grantee’s Service ends for any reason, the Grantee shall
forfeit and the Company shall automatically reacquire all Units for which the Service Condition has not been satisfied as of the time of such end of Grantee’s Service in accordance with Section 3 (the “Unvested
Units”), and the Grantee shall not be entitled to any payment therefor (the “Company Reacquisition Right”). 

4.2 Dividends, Distributions and Adjustments. Upon the occurrence of a dividend or distribution to the stockholders of
the Company paid in shares of Stock or other property, or any other adjustment upon a change in the capital structure of the Company as described in Section 7, any and all new, 

  
 5 

 
substituted or additional securities or other property to which the Grantee is entitled by reason of the Grantee’s ownership of Unvested Units shall be immediately subject to the Company
Reacquisition Right and included in the terms “Units” and “Unvested Units” for all purposes of the Company Reacquisition Right with the same force and effect as the Unvested Units immediately prior to the dividend, distribution
or adjustment, as the case may be. For purposes of determining the number of Units for which the Service Condition has been satisfied following a dividend, distribution or adjustment, credited Service shall include all Service with any corporation
which is a Participating Company at the time the Service is rendered, whether or not such corporation is a Participating Company both before and after any such event. 

5. SETTLEMENT OF THE UNITS. 

5.1 Issuance of Shares of Stock. Subject to the provisions of Section 5.3 below, the Company shall issue to the
Grantee on the Settlement Date with respect to each Vested Unit to be settled on such date one (1) share of Stock. 
 5.2 Beneficial
Ownership of Shares. A certificate for the shares acquired by the Grantee shall be registered in the name of the Grantee, or, if applicable, in the names of the heirs of the Grantee. 

5.3 Restrictions on Grant of the Units and Issuance of Shares. As of the date of this Agreement, the grant of the Units
and issuance of shares of Stock upon settlement of the Units have not been registered under federal or state securities laws, and as a result, shall be subject to compliance with all applicable requirements of federal, state or foreign law with
respect to such securities. No shares of Stock may be issued hereunder if the issuance of such shares would constitute a violation of any applicable federal, state or foreign securities laws or other law or regulations or the requirements of any
stock exchange or market system upon which the Stock may then be listed. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company’s legal counsel to be necessary to the
lawful issuance of any shares subject to this Agreement shall relieve the Company of any liability in respect of the failure to issue such shares as to which such requisite authority shall not have been obtained. As a condition to the settlement of
the Units, the Company may require the Grantee to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation and to make any representation or warranty with respect thereto as may be
requested by the Company. 
 5.4 Transfer of Shares. The Grantee may not transfer the shares of Stock issued upon settlement of the
Units except in compliance with applicable federal and state securities laws and the Company’s insider trading policy. 
 5.5
Fractional Shares. The Company shall not be required to issue fractional shares upon the settlement of the Units. 

6. TAX WITHHOLDING. 

Grantee understands and agrees that the Grantee is an independent contractor and not an employee of the Company. As a result, the Company will
not make deductions for taxes from any amounts payable to Grantee as a result of his Services to the Company or as a result of the vesting or settlement of the Units (except as otherwise required by applicable law or regulation). Any taxes imposed
on the Grantee due to Services to the Company (including upon the issuance, vesting and settlement of the Units) will be the sole responsibility of the Consultant. 

7. ADJUSTMENTS FOR CHANGES IN CAPITAL
STRUCTURE. 
 Subject to any required action by the stockholders of the Company and the requirements
of Section 409A of the Code to the extent applicable, in the event of any change in the Stock effected without receipt of consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization,
reclassification, stock dividend, stock split, reverse stock split, split-up, split-

  
 6 

 
off, spin-off, combination of shares, exchange of shares, or similar change in the capital structure of the Company, or in the event of payment of a dividend or distribution to the stockholders
of the Company in a form other than Stock (other than regular, periodic cash dividends paid on Stock pursuant to the Company’s dividend policy) that has a material effect on the Fair Market Value of shares of Stock, appropriate and
proportionate adjustments shall be made in the number of Units subject to this Agreement and/or the number and kind of shares or other property to be issued in settlement of the Units, in order to prevent dilution or enlargement of the
Grantee’s rights under this Agreement. For purposes of the foregoing, conversion of any convertible securities of the Company shall not be treated as “effected without receipt of consideration by the Company.” Any and all new,
substituted or additional securities or other property (other than regular, periodic cash dividends paid on Stock pursuant to the Company’s dividend policy) to which the Grantee is entitled by reason of ownership of Units acquired pursuant to
this Agreement will be immediately subject to the provisions of this Agreement on the same basis as all Units originally acquired hereunder. Any fractional Unit or share resulting from an adjustment pursuant to this Section shall be rounded down to
the nearest whole number. Such adjustments shall be determined by the Board, and its determination shall be final, binding and conclusive. 

8. RIGHTS AS A STOCKHOLDER OR
DIRECTOR. 
 The Grantee shall have no rights as a stockholder with respect to any shares which may be
issued in settlement of the Units until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). No adjustment shall be made for dividends,
distributions or other rights for which the record date is prior to the date the shares of Stock are issued, except as provided in Section 2.3 or Section 7. The Grantee understands and acknowledges that the Grantee’s Services are not
for any particular period of time, and that Grantee’s continued Service as a director is dependent on the continued nomination by the Company’s Board of Directors and election by the Company’s stockholders. Nothing in this Agreement
shall confer upon the Grantee any right to continue in the Service of a Participating Company or interfere in any way with any right of a Participating Company to end the Grantee’s Service at any time. 

9. LEGENDS. 

The Company may at any time place legends referencing any applicable federal, state or foreign securities law restrictions on all certificates
representing shares of Stock issued pursuant to this Agreement. The Grantee shall, at the request of the Company, promptly present to the Company any and all certificates representing shares acquired pursuant to this Agreement in the possession of
the Grantee in order to carry out the provisions of this Section. Unless otherwise specified by the Company, legends placed on such certificates may include, but shall not be limited to, the following: 

“THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD,
TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SECURITIES, THE SALE IS MADE IN ACCORDANCE WITH RULE 144 OR RULE 701 UNDER THE ACT, OR THE COMPANY RECEIVES AN OPINION OF
COUNSEL REASONABLY SATISFACTORY TO THE COMPANY, STATING THAT SUCH SALE, TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT.” 

10. COMPLIANCE WITH SECTION 409A. 

It is intended that any election, payment or benefit which is made or provided pursuant to or in connection with this Agreement that may
result in or relate to the deferral of compensation within the meaning of Section 409A of the Code (“Section 409A Deferred Compensation”) shall comply in all respects with the

  
 7 

 
applicable requirements of Section 409A of the Code (including applicable regulations or other administrative guidance thereunder, as determined by the Board in good faith) to avoid the
unfavorable tax consequences provided therein for non-compliance. In connection with effecting such compliance with Section 409A of the Code, the following shall apply: 

10.1 Separation from Service; Required Delay in Payment to Specified Grantee. Notwithstanding anything set forth herein to the contrary,
no amount payable pursuant to this Agreement on account of the Grantee’s end of Service which constitutes Section 409A Deferred Compensation shall be paid unless and until the Grantee has incurred a “separation from service”
within the meaning of Section 409A of the Code. Furthermore, to the extent that the Grantee is a “specified employee” within the meaning of the Section 409A as of the date of the Grantee’s separation from service, no amount
that constitutes a deferral of compensation which is payable on account of the Grantee’s separation from service shall be paid to the Grantee before the date (the “Delayed Payment Date”) which is first day
of the seventh month after the date of the Grantee’s separation from service or, if earlier, the date of the Grantee’s death following such separation from service. All such amounts that would, but for this Section, become payable prior to
the Delayed Payment Date will be accumulated and paid on the Delayed Payment Date. 
 10.2 Other Changes in Time of Payment. Neither
the Grantee nor the Company shall take any action to accelerate or delay the payment of any benefits under this Agreement in any manner which would not be in compliance with Section 409A of the Code. 

10.3 Amendments to Comply with Section 409A; Indemnification. Notwithstanding any other provision of this Agreement to the
contrary, the Company is authorized to amend this Agreement, to void or amend any election made by the Grantee under this Agreement and/or to delay the payment of any monies and/or provision of any benefits in such manner as may be determined by the
Company, in its discretion, to be necessary or appropriate to comply with Section 409A of the Code without prior notice to or consent of the Grantee. The Grantee hereby releases and holds harmless the Company, its directors, officers and
stockholders from any and all claims that may arise from or relate to any tax liability, penalties, interest, costs, fees or other liability incurred by the Grantee in connection with this Agreement, including as a result of the application of
Section 409A of the Code. 
 10.4 Advice of Independent Tax Advisor. The Company has not obtained a tax ruling or other
confirmation from the Internal Revenue Service with regard to the application of Section 409A to this Agreement, and the Company does not represent or warrant that this Agreement will avoid adverse tax consequences to the Grantee, including as
a result of the application of Section 409A of the Code. The Grantee hereby acknowledges that he or she has been advised to seek the advice of his or her own independent tax advisor prior to entering into this Agreement and is not relying upon
any representations of the Company or any of its agents as to the effect of or the advisability of entering into this Agreement. 
 11.
ADMINISTRATION. 
 All questions of interpretation concerning this Agreement or any other form of
agreement or other document employed by the Company in the administration of this Agreement shall be determined by the Board. All such determinations by the Board shall be final, binding and conclusive upon all persons having an interest in this
Agreement, unless fraudulent or made in bad faith. Any and all actions, decisions and determinations taken or made by the Board in the exercise of its discretion pursuant to this Agreement or other agreement thereunder (other than determining
questions of interpretation pursuant to the preceding sentence) shall be final, binding and conclusive upon all persons having an interest in this Agreement. Any officer of the Company shall have the authority to act on behalf of the Company with
respect to any matter, right, obligation, or election which is the responsibility of or which is allocated to the Company herein, provided the officer has apparent authority with respect to such matter, right, obligation, or election. 

  
 8 

 12. REPRESENTATIONS AND WARRANTIES
OF GRANTEE. 
 In connection with the acquisition of securities pursuant to this
Agreement, the Grantee hereby agrees, represents and warrants as follows: 
 12.1 Investment Intent. The Grantee is acquiring shares
of Stock pursuant to this Agreement solely for the Grantee’s own account for investment and not with a view to or for sale in connection with any distribution of the shares or any portion thereof and not with any present intention of selling,
offering to sell or otherwise disposing of or distributing the shares or any portion thereof in any transaction other than a transaction exempt from registration under the Securities Act. The Grantee further represents that the entire legal and
beneficial interest of the shares is being acquired, and will be held, for the account of the Grantee only and neither in whole nor in part for any other person. 

12.2 Absence of Solicitation. The Grantee was not presented with or solicited by any form of general solicitation or general
advertising, including, but not limited to, any advertisement, article, notice, or other communication published in any newspaper, magazine, or similar media, or broadcast over television, radio or similar communications media, or presented at any
seminar or meeting whose attendees have been invited by any general solicitation or general advertising. 
 12.3 Capacity to Protect
Interests. The Grantee has either (a) a preexisting personal or business relationship with the Company or any of its officers, directors, or controlling persons, consisting of personal or business contacts of a nature and duration to enable
the Grantee to be aware of the character, business acumen and general business and financial circumstances of the person with whom such relationship exists, or (b) such knowledge and experience in financial and business matters (or has relied
on the financial and business knowledge and experience of the Grantee’s professional advisor who is unaffiliated with and who is not, directly or indirectly, compensated by the Company or any affiliate or selling agent of the Company) as to
make the Grantee capable of evaluating the merits and risks of the investment in shares acquired pursuant to this Agreement and to protect the Grantee’s own interests in the transaction, or (c) both such relationship and such knowledge and
experience. 
 12.4 Restricted Securities. The Grantee understands and acknowledges that: 

(a) The issuance to Grantee of shares pursuant to this Agreement has not been registered under the Securities Act, and the shares must be held
indefinitely unless a transfer of the shares is subsequently registered under the Securities Act or an exemption from such registration is available, and that the Company is under no obligation to register the shares; and 

(b) The Company will make a notation in its records of the aforementioned restrictions on transfer and legends. 

12.5 Disposition Under Rule 144. The Grantee understands that if the shares acquired pursuant to this Agreement are not registered
prior to the Company’s issuance of such shares, the share will be restricted securities within the meaning of Rule 144 promulgated under the Securities Act (“Rule 144”). In addition, Grantee understands that he is
an “affiliate” for purposes of Rule 144, and as such, remains subject to the “affiliate” restrictions set forth in Rule 144. As a result, Grantee understands and agrees that any future transfers of the Stock must be
conducted in compliance with Rule 144. 
 12.6 Reliance by Company. The Grantee understands that the shares acquired pursuant to this
Agreement have not been registered under the Securities Act or under applicable state securities laws by reason of specific exemptions therefrom, which exemptions may depend upon, among other things, the bona fide nature of the Grantee’s
representations as expressed herein. The Grantee understands that the Company is relying on the Grantee’s representations and warrants that the Company is entitled to rely on such representations and that such reliance is reasonable. 

  
 9 

 13. MISCELLANEOUS PROVISIONS. 

13.1 Termination or Amendment. The Board may terminate or amend this Agreement at any time; provided, however, no such termination or
amendment may adversely affect the Grantee’s rights under this Agreement without the consent of the Grantee unless such termination or amendment is necessary to comply with applicable law or government regulation, including, but not limited to,
Section 409A of the Code. No amendment or addition to this Agreement shall be effective unless in writing. 
 13.2
Nontransferability of Units. Prior to the issuance of shares of Stock on the applicable Settlement Date, neither this Agreement nor any Units subject to this Agreement shall be subject in any manner to anticipation, alienation, sale,
exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Grantee or the Grantee’s beneficiary, except transfer by will or by the laws of descent and distribution. All rights with respect to this Agreement shall be
exercisable during the Grantee’s lifetime only by the Grantee or the Grantee’s guardian or legal representative. 
 13.3
Further Instruments. The parties hereto agree to execute such further instruments and to take such further action as may reasonably be necessary to carry out the intent of this Agreement. 

13.4 Binding Effect. This Agreement shall inure to the benefit of the successors and assigns of the Company and, subject to the
restrictions on transfer set forth herein, be binding upon the Grantee and the Grantee’s heirs, executors, administrators, successors and assigns. 

13.5 Delivery of Documents and Notices. Any document relating to this Agreement or any notice required or permitted hereunder shall be
given in writing and shall be deemed effectively given (except to the extent that this Agreement provides for effectiveness only upon actual receipt of such notice) upon personal delivery, electronic delivery at the e-mail address, if any, provided
for the Grantee by a Participating Company, or upon deposit in the U.S. Post Office or foreign postal service, by registered or certified mail, or with a nationally recognized overnight courier service, with postage and fees prepaid, addressed to
the other party at the address of such party set forth below or at such other address as such party may designate in writing from time to time to the other party. 

(a) Description of Electronic Delivery. This Agreement and any reports of the Company provided generally to the Company’s
stockholders may be delivered to the Grantee electronically. Such means of electronic delivery may include but do not necessarily include the delivery of a link to a Company intranet or the Internet site of a third party involved in administering
this Agreement, the delivery of the document via e-mail or such other means of electronic delivery specified by the Company. 
 (b)
Consent to Electronic Delivery. The Grantee acknowledges that the Grantee has read Section 13.5(a) of this Agreement and consents to the electronic delivery of the documents described in such Section. The Grantee acknowledges that he or
she may receive from the Company a paper copy of any documents delivered electronically at no cost to the Grantee by contacting the Company by telephone or in writing. The Grantee further acknowledges that the Grantee will be provided with a paper
copy of any documents if the attempted electronic delivery of such documents fails. The Grantee may revoke his or her consent to the electronic delivery of documents described in Section 13.5(a) or may change the electronic mail address to
which such documents are to be delivered (if Grantee has provided an electronic mail address) at any time by notifying the Company of such revoked consent or revised e-mail address by telephone, postal service or electronic mail. Finally, the
Grantee understands that he or she is not required to consent to electronic delivery of documents described in Section 13.5(a). 
 13.6
Integrated Agreement. This Agreement shall constitute the entire understanding and agreement of the Grantee and the Company with respect to the subject matter contained herein and shall supersede any prior agreements, understandings,
restrictions, representations, or warranties between the Grantee and the Company with respect to such subject matter. To the extent contemplated herein, the provisions of this Agreement shall survive any settlement of the Units and shall remain in
full force and effect. 

  
 10 

 13.7 Applicable Law. This Agreement will be governed by the laws of the State of
California, without giving effect to the conflict of law principles thereof. For purposes of litigating any dispute that arises under this Agreement, the parties hereby submit to and consent to the jurisdiction of the State of California, and agree
that such litigation will be conducted in the courts of San Diego County, California, or the federal courts for the United States for the Southern District of California, and no other courts, where this Agreement is made and/or to be performed. 

13.8 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 
  

							
		 		 	PURE BIOSCIENCE, INC.
				
	Date:
                                        
	 		 	By: 	 	 
		 		 	Title:	 	 
		 		 	Address: 	 	 
		 		 		 	 

 ACCEPTANCE 

The Grantee represents that the Grantee has read and is familiar with the terms and provisions of this Agreement and hereby accepts the Award
subject to all of the terms and provisions hereof. The Grantee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Board of Directors of the Company upon any questions arising under this Agreement. 

 

							
		 		 	GRANTEE
			
	Date:
                                        
	 		 	  

		 		 		 	
		 		 	Address: 	 	 
		 		 		 	 

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]